Advances in targeting the WNT/β-catenin signaling pathway in cancer

Avradip Chatterjee; Sayan Paul; Bharti Bisht; Shelley Bhattacharya; Sudhakar Sivasubramaniam; Manash K. Paul

doi:10.1016/j.drudis.2021.07.007

Advances in targeting the WNT/β-catenin signaling pathway in cancer

Avradip Chatterjee
, Sayan Paul
, Bharti Bisht
, Shelley Bhattacharya
, Sudhakar Sivasubramaniam
, Manash K. Paul^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

105 Citations (Scopus)

Abstract

WNT/β-catenin signaling orchestrates various physiological processes, including embryonic development, growth, tissue homeostasis, and regeneration. Abnormal WNT/β-catenin signaling is associated with various cancers and its inhibition has shown effective antitumor responses. In this review, we discuss the pathway, potential targets for the development of WNT/β-catenin inhibitors, available inhibitors, and their specific molecular interactions with the target proteins. We also discuss inhibitors that are in clinical trials and describe potential new avenues for therapeutically targeting the WNT/β-catenin pathway. Furthermore, we introduce emerging strategies, including artificial intelligence (AI)-assisted tools and technology-based actionable approaches, to translate WNT/β-catenin inhibitors to the clinic for cancer therapy.

Original language	English
Pages (from-to)	82-101
Number of pages	20
Journal	Drug Discovery Today
Volume	27
Issue number	1
DOIs	https://doi.org/10.1016/j.drudis.2021.07.007
Publication status	Published - 01-2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Pharmacology
Drug Discovery

Access to Document

10.1016/j.drudis.2021.07.007

Cite this

@article{aa12369d8845407d95f8fa0227d367ba,

title = "Advances in targeting the WNT/β-catenin signaling pathway in cancer",

abstract = "WNT/β-catenin signaling orchestrates various physiological processes, including embryonic development, growth, tissue homeostasis, and regeneration. Abnormal WNT/β-catenin signaling is associated with various cancers and its inhibition has shown effective antitumor responses. In this review, we discuss the pathway, potential targets for the development of WNT/β-catenin inhibitors, available inhibitors, and their specific molecular interactions with the target proteins. We also discuss inhibitors that are in clinical trials and describe potential new avenues for therapeutically targeting the WNT/β-catenin pathway. Furthermore, we introduce emerging strategies, including artificial intelligence (AI)-assisted tools and technology-based actionable approaches, to translate WNT/β-catenin inhibitors to the clinic for cancer therapy.",

author = "Avradip Chatterjee and Sayan Paul and Bharti Bisht and Shelley Bhattacharya and Sudhakar Sivasubramaniam and Paul, \{Manash K.\}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2022",

month = jan,

doi = "10.1016/j.drudis.2021.07.007",

language = "English",

volume = "27",

pages = "82--101",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "1",

}

TY - JOUR

T1 - Advances in targeting the WNT/β-catenin signaling pathway in cancer

AU - Chatterjee, Avradip

AU - Paul, Sayan

AU - Bisht, Bharti

AU - Bhattacharya, Shelley

AU - Sivasubramaniam, Sudhakar

AU - Paul, Manash K.

PY - 2022/1

Y1 - 2022/1

N2 - WNT/β-catenin signaling orchestrates various physiological processes, including embryonic development, growth, tissue homeostasis, and regeneration. Abnormal WNT/β-catenin signaling is associated with various cancers and its inhibition has shown effective antitumor responses. In this review, we discuss the pathway, potential targets for the development of WNT/β-catenin inhibitors, available inhibitors, and their specific molecular interactions with the target proteins. We also discuss inhibitors that are in clinical trials and describe potential new avenues for therapeutically targeting the WNT/β-catenin pathway. Furthermore, we introduce emerging strategies, including artificial intelligence (AI)-assisted tools and technology-based actionable approaches, to translate WNT/β-catenin inhibitors to the clinic for cancer therapy.

AB - WNT/β-catenin signaling orchestrates various physiological processes, including embryonic development, growth, tissue homeostasis, and regeneration. Abnormal WNT/β-catenin signaling is associated with various cancers and its inhibition has shown effective antitumor responses. In this review, we discuss the pathway, potential targets for the development of WNT/β-catenin inhibitors, available inhibitors, and their specific molecular interactions with the target proteins. We also discuss inhibitors that are in clinical trials and describe potential new avenues for therapeutically targeting the WNT/β-catenin pathway. Furthermore, we introduce emerging strategies, including artificial intelligence (AI)-assisted tools and technology-based actionable approaches, to translate WNT/β-catenin inhibitors to the clinic for cancer therapy.

UR - https://www.scopus.com/pages/publications/85111518850

UR - https://www.scopus.com/pages/publications/85111518850#tab=citedBy

U2 - 10.1016/j.drudis.2021.07.007

DO - 10.1016/j.drudis.2021.07.007

M3 - Review article

C2 - 34252612

AN - SCOPUS:85111518850

SN - 1359-6446

VL - 27

SP - 82

EP - 101

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 1

ER -

Advances in targeting the WNT/β-catenin signaling pathway in cancer

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this